|
May 9
|
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
|
|
May 8
|
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
|
|
May 6
|
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
|
|
Apr 29
|
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
|
|
Apr 22
|
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
|
|
Apr 18
|
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
|
|
Apr 16
|
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
|
|
Apr 9
|
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
|
|
Apr 8
|
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
|
|
Apr 3
|
Jaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)
|
|
Apr 2
|
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcript
|
|
Apr 2
|
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
|
|
Apr 2
|
Q4 2023 Jaguar Health Inc Earnings Call
|
|
Apr 1
|
Jaguar Health Reports 2023 Financial Results
|
|
Mar 27
|
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
|
|
Mar 20
|
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
|
|
Feb 23
|
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
|
|
Feb 12
|
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
|
|
Dec 24
|
11 Popular Penny Stocks on Robinhood
|
|
Dec 18
|
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 61%
|